AI assistant
Summit Therapeutics Inc. — Director's Dealing 2024
Aug 23, 2024
30436_dirs_2024-08-23_7b7bbc48-4d09-416a-a2e9-d22b52f3fa6b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2024-08-23
Reporting Person: Zanganeh Mahkam (Director, Chief Executive Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-08-23 | Performance Stock Option (right to buy) | $1.06 | A | 260000 | Acquired | 2032-06-28 | Common Stock (260000) | Direct |
| 2024-08-23 | Performance Stock Option (right to buy) | $1.29 | A | 100000 | Acquired | 2032-09-09 | Common Stock (100000) | Direct |
| 2024-08-23 | Performance Stock Option (right to buy) | $1.68 | A | 2397640 | Acquired | 2033-10-13 | Common Stock (2397640) | Direct |
Footnotes
F1: These performance-based stock options vested on August 23, 2024, upon the attainment of the satisfaction of certain financial performance objectives. Note this does not include an additional 1,040,000 shares underlying options which were granted on June 28, 2022, that remain subject to the satisfaction of performance conditions.
F2: Not applicable.
F3: These performance-based stock options vested on August 23, 2024, upon the attainment of the satisfaction of certain financial performance objectives. Note this does not include an additional 400,000 shares underlying options which were granted on September 9, 2022 that remain subject to the satisfaction of performance conditions.
F4: These performance-based stock options vested on August 23, 2024, upon the attainment of the satisfaction of certain financial performance objectives. Note this does not include an additional 9,590,558 shares underlying options which were granted on October 13, 2023 that remain subject to the satisfaction of performance conditions.